Morgan Stanley’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-7,932
| Closed | -$5.54K | – | 7773 |
|
|
2023
Q1 | $5.54K | Sell |
7,932
-3,251
| -29% | -$2.99K | ﹤0.01% | 7027 |
|
|
2022
Q4 | $10.1K | Sell |
11,183
-212,633
| -95% | -$616K | ﹤0.01% | 6932 |
|
|
2022
Q3 | $1.34M | Sell |
223,816
-22,876
| -9% | -$130K | ﹤0.01% | 4697 |
|
|
2022
Q2 | $1.02M | Buy |
246,692
+234,307
| +1,892% | +$826K | ﹤0.01% | 5004 |
|
|
2022
Q1 | $47K | Sell |
12,385
-42,335
| -77% | -$191K | ﹤0.01% | 6741 |
|
|
2021
Q4 | $246K | Sell |
54,720
-47,370
| -46% | -$241K | ﹤0.01% | 5957 |
|
|
2021
Q3 | $475K | Sell |
102,090
-250,363
| -71% | -$1.33M | ﹤0.01% | 5532 |
|
|
2021
Q2 | $2.48M | Sell |
352,453
-224,569
| -39% | -$1.21M | ﹤0.01% | 4468 |
|
|
2021
Q1 | $3.41M | Sell |
577,022
-416,601
| -42% | -$2.52M | ﹤0.01% | 3808 |
|
|
2020
Q4 | $4.58M | Buy |
993,623
+747,288
| +303% | +$3.22M | ﹤0.01% | 3356 |
|
|
2020
Q3 | $958K | Buy |
246,335
+241,648
| +5,156% | +$4.86M | ﹤0.01% | 4238 |
|
|
2020
Q2 | $135K | Buy |
4,687
+441
| +10% | +$10.2K | ﹤0.01% | 5256 |
|
|
2020
Q1 | $91K | Sell |
4,246
-1,690
| -28% | -$38.4K | ﹤0.01% | 5224 |
|
|
2019
Q4 | $117K | Buy |
5,936
+5,836
| +5,836% | +$82.9K | ﹤0.01% | 5605 |
|
|
2019
Q3 | $2K | Buy |
+100
| New | +$1.55K | ﹤0.01% | 6503 |
|
Morgan Stanley's STSA Position: Q2 2023 in Review
Morgan Stanley sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q2 2023, closing a stake of 7,932 shares — an estimated $5.54K sold.
Morgan Stanley first reported a position in STSA in Q3 2019 and held it in 15 quarters. The position peaked at $4.58M in Q4 2020. 0 funds tracked by Wall St. Rank hold STSA as of Q2 2023.
- Morgan Stanley reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Morgan Stanley sold 7,932 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $5.54K.
- Morgan Stanley first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 15 quarters.
- Morgan Stanley's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $4.58M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q2 2023.
Based on Morgan Stanley's 13F filing for Q2 2023, filed 14 Aug 2023.